Tremfya Evropska unija - slovenščina - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Tremfya 100 mg raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

tremfya 100 mg raztopina za injiciranje

janssen-cilag international nv - guselkumab - raztopina za injiciranje - guselkumab 100 mg / 1 brizga - guselkumab

Taltz Evropska unija - slovenščina - EMA (European Medicines Agency)

taltz

eli lilly and company (ireland) limited - ixekizumab - psoriaza - imunosupresivi - plaketo psoriasistaltz je primerna za zdravljenje zmerno do hudo psoriazo v plakih pri odraslih, ki so kandidati za sistemsko terapijo. psoriatični arthritistaltz, samostojno ali v kombinaciji z metotreksatom, je primerna za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih, ki so se odzvali neustrezno ali ki so nestrpni do enega ali več bolezni spreminjajo anti-revmatičnih drog (dmard) terapije.

Spevigo Evropska unija - slovenščina - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - psoriaza - imunosupresivi - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.